Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma.[1] As of September 2009[update], it is undergoing Phase III clinical trials.[2] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[3]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (primate/human) |
| Target | CD80 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
References
edit- ^ Ebadi M, Sadeghi MA, Reddy NM, Rezaei N (2020). "Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma". In Rezaei M (ed.). Cancer immunology: cancer immunotherapy for organ-specific tumors (Second ed.). Cham: Springer Nature. p. 178. ISBN 978-3-03-057949-4.
- ^ "Biogen Idec: Pipeline". Archived from the original on 2008-05-17. Retrieved 2009-09-24.
- ^ WHO Drug Information
External links
edit
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |